KAM
PACB icon

Kassirer Asset Management’s Pacific Biosciences PACB Stock Holding History

Kassirer Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-182,950
Closed -$1.35M – 16
2018
Q4 		$1.35M Buy
+182,950
New +$1.16M 1.24% 22

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

Kassirer Asset Management's PACB Position: Q1 2019 in Review

Kassirer Asset Management sold out of Pacific Biosciences (PACB) in Q1 2019, closing a stake of 182,950 shares — an estimated $1.35M sold.

Kassirer Asset Management first reported a position in PACB in Q4 2018 and held it in 1 quarter. The position peaked at $1.35M in Q4 2018. 160 funds tracked by Wall St. Rank hold PACB as of Q1 2019.

  • Kassirer Asset Management reported no remaining Pacific Biosciences position as of Q1 2019 after selling out during the quarter.
  • Kassirer Asset Management sold 182,950 Pacific Biosciences shares in Q1 2019, an estimated $1.35M.
  • Kassirer Asset Management first reported a position in Pacific Biosciences in Q4 2018 and held it in 1 quarter.
  • Kassirer Asset Management's Pacific Biosciences position peaked at $1.35M in Q4 2018.
  • 160 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2019.

Based on Kassirer Asset Management's 13F filing for Q1 2019, filed 10 May 2019.